

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: US 6184359 B1

L3: Entry 1 of 2

File: USPT

Feb 6, 2001

US-PAT-NO: 6184359

DOCUMENT-IDENTIFIER: US 6184359 B1

TITLE: Antibodies to epithelium-derived T-cell factor

DATE-ISSUED: February 6, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Anderson; Dirk M.	Seattle	WA		
Eisenman; June R.	Seattle	WA		
Fung; Victor	Redmond	WA		
Rauch; Charles	Bainbridge Island	WA		

US-CL-CURRENT: 530/388.23; 424/130.1, 424/134.1, 424/139.1, 424/141.1, 424/142.1,  
424/145.1, 424/158.1, 435/325, 435/326, 435/328, 435/331, 435/335, 435/346, 435/352,  
530/387.9, 530/388.1, 530/388.15, 530/389.1, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC
Draw	Desc	Image									

☐ 2. Document ID: US 5892001 A

L3: Entry 2 of 2

File: USPT

Apr 6, 1999

US-PAT-NO: 5892001

DOCUMENT-IDENTIFIER: US 5892001 A

TITLE: Epithelium-derived T-cell factor antibodies

DATE-ISSUED: April 6, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Anderson; Dirk M.	Seattle	WA		
Eisenman; June R.	Seattle	WA		
Fung; Victor	Redmond	WA		
Rauch; Charles	Bainbridge Island	WA		

US-CL-CURRENT: 530/387.9; 435/326, 435/331, 435/335, 530/388.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC
Draw. Desc	Image										

---

[Generate Collection](#)[Print](#)

Terms	Documents
5892001	2

---

**Display Format:**[CIT](#)[Change Format](#)[Previous Page](#)[Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: US 6184359 B1

L2: Entry 1 of 1

File: USPT

Feb 6, 2001

US-PAT-NO: 6184359DOCUMENT-IDENTIFIER: US 6184359 B1

TITLE: Antibodies to epithelium-derived T-cell factor

DATE-ISSUED: February 6, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Anderson; Dirk M.	Seattle	WA		
Eisenman; June R.	Seattle	WA		
Fung; Victor	Redmond	WA		
Rauch; Charles	Bainbridge Island	WA		

US-CL-CURRENT: 530/388.23; 424/130.1, 424/134.1, 424/139.1, 424/141.1, 424/142.1,  
424/145.1, 424/158.1, 435/325, 435/326, 435/328, 435/331, 435/335, 435/346, 435/352,  
530/387.9, 530/388.1, 530/388.15, 530/389.1, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KAMC

[Generate Collection](#)[Print](#)

Terms	Documents
6184359	1

**Display Format:**[CIT](#)[Change Format](#)[Previous Page](#)[Next Page](#)

**WEST**

Generate Collection

Print

L4: Entry 1 of 12

File: USPT

Feb 5, 2002

US-PAT-NO: 6344192

DOCUMENT-IDENTIFIER: US 6344192 B1

TITLE: Use of interleukin-15

DATE-ISSUED: February 5, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grooten; Johan Adriaan Marc	Lovendegem			BEX
Dooms; Hans Peter Raf	Ypres			BEX
Fiers; Walter Charles	Destelbergen			BEX

US-CL-CURRENT: 424/85.2; 424/85.1, 435/386, 435/69.5, 435/69.52, 530/351, 930/140,  
930/141

## CLAIMS:

What is claimed is:

1. A method of stimulating formation and promoting survival of memory T cells which recognize a specific antigen in a mammal in need thereof, comprising:

administering IL-15 or active variants thereof capable of generating memory T-cells, wherein administration occurs after an ongoing immune response to said specific antigen to enhance the secondary/memory response elicited by a renewed contact with said antigen.

2. A method according to claim 1 for manipulating viability of memory cells generated after an ongoing immune response to said specific antigen and after clearance of said antigen.

3. A method according to claim 1 for manipulating responsiveness of memory cells to a new encounter with antigen.

4. A method according to claim 1, wherein responsiveness towards renewed antigen challenge of said memory cells is enhanced.

5. A method according to claim 1 for protecting ex vivo propagated T lymphocytes against cells death in absence of growth factor.

6. A method according to claim 1, wherein the memory cells are CD4.sup.+ T lymphocytes.

7. A pharmaceutical composition comprising ex vivo cultivated T lymphocytes, treated with IL-15 or active variants thereof, during the ex vivo cultivation procedure.